Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2015

View Archived Issues

ODYSSEY studies demonstrate greater LDL cholesterol reductions for alirocumab over placebo

New NIAID grant supports Inovio's collaborative HIV program

NantWorks and Sorrento Therapeutics establish new cancer immunotherapy collaboration

The Icahn School of Medicine at Mount Sinai presents Brd4 inhibitors

Cloud Pharmaceuticals and University of Florida collaborate on MTH1 inhibitors for cancer

Esperion's phase IIb study of ETC-1002 in hypercholesterolemia meets primary endpoint

Melphalan flufenamide receives U.S. orphan drug status for multiple myeloma

Aldeyra Therapeutics opens enrollment in Sjogren-Larsson syndrome trial

Pharmalink acquires osteoarthritis candidate from Synartro

Coherus finalizes CHS-1701 BLA-enabling program and begins pivotal PK study

Ezetimibe/simvastatin combination improves clinical efficacy in ACS patients

NovImmune's HLH trial of NI-0501 allows first-line treatment after protocol amendment

FDA approves Cholbam for rare bile acid synthesis disorders

Novogen reports on potential of Anisina to become new chemotherapy

Hsa-miRNA-181c shows potential as a new diagnostic marker for ACLF

Astellas submits supplemental NDA for Kiklin in Japan

Hanmi Pharmaceutical launches phase II trial of HM-61713

Collagen-targeted nanoparticles containing Ac2-26 peptide provide insight into atherosclerosis

Emergent manufactures MVA EBOZ Ebola vaccine candidate under new agreements

Prexa Pharmaceuticals patents monoamine transporter ligands

Kyoto Pharmaceutical develops novel aromatic compounds

French researchers report development of MMP inhibitors

Chinese researchers report mTOR and PI3Kalpha inhibitors

FDA extends Kalydeco approval to younger children with cystic fibrosis

AstraZeneca and Daiichi Sankyo sign U.S. co-commercialization agreement for Movantik

Case report of emergency postexposure vaccination with VSVdeltaG-ZEBOV

Allena reports phase IIa data on ALLN-177 for the treatment of hyperoxaluria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...